FERNISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FERNISONE (FERNISONE).
FERNISONE is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
| Metabolism | Metabolized primarily by CYP3A4 in the liver to inactive metabolites. |
| Excretion | Renal excretion of unchanged drug and metabolites: ~60% (30% unchanged, 30% metabolites). Biliary/fecal elimination: ~35% (primarily as metabolites). Minor metabolic clearance via CYP3A4. About 5% eliminated in sweat and saliva. |
| Half-life | Terminal elimination half-life: 18-24 hours in healthy adults. In elderly (age >65), half-life increases to 30-36 hours due to reduced renal function. In moderate renal impairment (CrCl 30-60 mL/min), half-life extends to 40-48 hours. Clinical context: requires dose adjustment in renal impairment; steady-state reached in 3-5 days. |
| Protein binding | Approximately 92-96% bound to serum albumin (primarily) and alpha-1-acid glycoprotein (minor). In hypoalbuminemia (e.g., cirrhosis, nephrotic syndrome), free fraction increases significantly, enhancing pharmacodynamic effect. |
| Volume of Distribution | Volume of distribution (Vd): 0.18-0.25 L/kg (12-17.5 L for 70 kg adult). This low Vd indicates limited extravascular distribution, primarily in central compartment (plasma and interstitial fluid). Clinical meaning: reflects poor tissue penetration, consistent with high protein binding; loading dose may not be required. |
| Bioavailability | Oral: 75-85% (tablet) due to first-pass metabolism; reduced to 60-70% with food. Intravenous: 100%. Topical: approximately 5-15% (systemic absorption depends on application area and skin integrity; occlusive dressing increases to 30%.) |
| Onset of Action | Oral immediate-release: 1-2 hours (peak effect at 4-6 hours). Intravenous: 15-30 minutes (rapid onset for acute conditions). Intramuscular: 30-60 minutes. Topical (cream): 2-4 hours for local anti-inflammatory effect. |
| Duration of Action | Oral: 12-24 hours (single dose); with repeated dosing, anti-inflammatory effect persists for duration of therapy. Intravenous: 6-12 hours (acute effect). Topical: 8-12 hours after application. Clinical notes: duration may be prolonged in hepatic impairment due to reduced clearance; for chronic use, duration is limited by cumulative toxicity. |
| Molecular Weight | 358.43 |
40 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for any GFR level |
| Liver impairment | Child-Pugh A: 40 mg once daily; Child-Pugh B: 30 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | 0.5 mg/kg orally once daily; maximum 40 mg/day |
| Geriatric use | Initiate at 20 mg orally once daily; titrate based on response and tolerability |
| 1st trimester | Contraindicated due to teratogenic effects (cleft palate, cardiac anomalies) observed in animal studies and limited human data. Avoid use in first trimester unless no safer alternative. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause fetal adrenal suppression, growth restriction. Monitor fetal growth. |
| 3rd trimester | Use caution; risk of neonatal adrenal suppression, hypotonia, and withdrawal symptoms. Avoid chronic or high-dose use near term. |
Clinical note
Comprehensive clinical and safety monograph for FERNISONE (FERNISONE).
| Placental transfer | FERNISONE readily crosses the placenta. Cord blood concentrations are approximately 10-30% of maternal plasma concentrations. Active metabolite (prednisolone) also crosses but is partially inactivated by placental 11β-HSD2 enzyme. |
| Breastfeeding | FERNISONE is excreted into breast milk in low amounts (estimated infant dose <10% of maternal weight-adjusted dose). However, long-term use may affect infant adrenal function or growth. Monitor infant for signs of adrenal suppression (poor feeding, vomiting, lethargy). Consider pumping and discarding milk for 4 hours after maternal dose to minimize exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
Systemic fungal infectionsHypersensitivity to FERNISONE or any excipientAdministration of live or live-attenuated vaccines (due to immunosuppression)Severe immunosuppression (e.g., HIV with low CD4 count, active tuberculosis) unless specifically indicated
| Precautions | May cause adrenal suppression with prolonged use, Increased risk of infections, Osteoporosis with long-term use, Hyperglycemia, Growth retardation in children, Cushing's syndrome with high doses |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit sodium intake to reduce fluid retention; increase potassium intake through foods like bananas and potatoes. Avoid alcohol as it may increase risk of gastrointestinal bleeding. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FERNISONE is a corticosteroid with known teratogenic potential in animal studies. In humans, first trimester use is associated with increased risk of cleft lip and palate (odds ratio 3.5). Second and third trimester exposure may lead to intrauterine growth restriction, adrenal suppression, and increased risk of gestational diabetes. Benefits must outweigh risks. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and adrenal function. Perform serial fetal ultrasounds for growth restriction. Monitor for signs of maternal infection. Assess fetal adrenal function via nonstress test and biophysical profile in third trimester. |
| Fertility Effects | FERNISONE may suppress hypothalamic-pituitary-adrenal axis, potentially leading to menstrual irregularities and impaired ovulation. Reversible upon dose reduction or discontinuation. No direct effect on sperm parameters in males. |
| Clinical Pearls | FERNISONE is a synthetic corticosteroid with high glucocorticoid activity and minimal mineralocorticoid effects. Monitor for adrenal suppression during prolonged therapy; taper dose gradually. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease. Consider prophylactic therapy for Pneumocystis jirovecii pneumonia when used with other immunosuppressants. Avoid live vaccines during treatment. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly as it may cause adrenal insufficiency. · Report any unusual weight gain, swelling, or shortness of breath. · Avoid exposure to infections; notify your doctor if you develop fever or illness. · Do not receive live vaccines while taking this medication. · Inform all healthcare providers you are taking this drug, especially before surgery. |